Associations of the Intake of Individual and Multiple Flavonoids with Metabolic Dysfunction Associated Steatotic Liver Disease in the United States

被引:0
作者
Wang, Chen [1 ,2 ]
Li, Mengchu [1 ,2 ]
Zhang, Jiali [1 ,2 ]
Li, Hongguang [3 ]
Li, Yue [3 ]
Huang, Siyu [1 ,2 ]
Zhu, Huilian [1 ,2 ]
Liu, Zhaoyan [1 ,2 ]
机构
[1] Sun Yat Sen Univ, Sch Publ Hlth, Dept Nutr, 74 Zhong Shan Rd 2, Guangzhou 510080, Peoples R China
[2] Sun Yat Sen Univ, Sch Publ Hlth, Guangdong Prov Key Lab Food Nutr & Hlth, Guangzhou 510080, Peoples R China
[3] Zhongshan City Peoples Hosp, Dept Clin Nutr, Zhongshan 528400, Peoples R China
关键词
flavonoids; MASLD; NHANES; WQS; NAFLD; OXIDATIVE STRESS; PATHOGENESIS; UPDATE; NAFLD; DIET;
D O I
10.3390/nu17020205
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background: Evidence regarding the individual and combined impact of dietary flavonoids on the risk of metabolic dysfunction associated with steatotic liver disease (MASLD) remains scarce. Our objective is to evaluate the association between individual and multiple dietary flavonoids with MASLD in adults. Methods: Data sets were obtained from the National Health and Nutrition Examination Survey (NHANES), 2017-2018. In total, 2581 participants aged over 18 years, with complete information on dietary flavonoid intake, MASLD, and covariates, were included. Flavonoid intake was energy-adjusted using the residual method. Logistic regression analysis was employed to examine the impact of total flavonoid intake on MASLD. Weighted quantile sum (WQS) analyses were used to evaluate the combined and individual effects of flavonoids on MASLD and to identify the predominant types with the most significant contribution to MASLD prevention. Results: The highest tertile of total flavonoid intake was associated with a 29% reduction in the risk of MASLD compared to the lowest tertile after multivariable adjustments (OR: 0.71, 95% CI: 0.51-0.97). The WQS analysis revealed that anthocyanidins, flavones, and flavanones were the most critical contributors among six subclasses (weights = 0.317, 0.279, and 0.227, respectively) and naringenin, apigenin, and delphinidin were the most critical contributors among 29 monomers. (weights = 0.240, 0.231, and 0.114, respectively). Also, a higher intake of anthocyanidins, flavones, naringenin, apigenin, and delphinidin was linked to a reduced risk of MASLD (p < 0.05).Conclusions: Our findings suggested that a higher flavonoid intake is associated with a lower risk of MASLD, with anthocyanidins, flavones, flavanones, naringenin, apigenin, delphinidin, and myricetin contributing most to the protective effects of flavonoids.
引用
收藏
页数:16
相关论文
共 50 条
  • [31] Extracellular Vesicles and Their Correlation with Inflammatory Factors in an Experimental Model of Steatotic Liver Disease Associated with Metabolic Dysfunction
    Keingeski, Melina Belen
    Longo, Larisse
    Brum da Silva Nunes, Vitoria
    Figueiro, Fabricio
    Dallemole, Danieli Rosane
    Pohlmann, Adriana Raffin
    Vier Schmitz, Thalia Michele
    da Costa Lopez, Patricia Luciana
    Alvares-da-Silva, Mario Reis
    Uribe-Cruz, Carolina
    METABOLIC SYNDROME AND RELATED DISORDERS, 2024, 22 (05) : 394 - 401
  • [32] Psychosocial risks in metabolic dysfunction-associated steatotic liver disease
    Astrom, Hanne
    Takami Lageborn, Christine
    Hagstrom, Hannes
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2025, 19 (03) : 273 - 290
  • [33] Metabolic dysfunction-associated steatotic liver disease: A silent pandemic
    Samanta, Arghya
    Sen Sarma, Moinak
    WORLD JOURNAL OF HEPATOLOGY, 2024, 16 (04)
  • [34] Noninvasive Tests to Assess Fibrosis and Disease Severity in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic-Dysfunction-Associated Steatohepatitis
    Tincopa, Monica A.
    Loomba, Rohit
    SEMINARS IN LIVER DISEASE, 2024, 44 (03) : 287 - 299
  • [35] Metabolic-associated steatotic liver disease and hepatocellular carcinoma
    Catalano, Giovanni
    Chatzipanagiotou, Odysseas P.
    Kawashima, Jun
    Pawlik, Timothy M.
    EXPERT OPINION ON PHARMACOTHERAPY, 2024, 25 (17) : 2283 - 2291
  • [36] Phenotypes of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatocellular Carcinoma
    Esteban, Jesus Rivera-
    Munoz-Martinez, Sergio
    Higuera, Monica
    Sena, Elena
    Bermudez-Ramos, Maria
    Banares, Juan
    Martinez-Gomez, Maria
    Cusido, M. Serra
    Jimenez-Masip, Alba
    Francque, Sven M.
    Tacke, Frank
    Minguez, Beatriz
    Pericas, Juan M.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2024, 22 (09) : 1774 - 1789.e8
  • [37] Association between the Fatty Liver Index, Metabolic Dysfunction-Associated Steatotic Liver Disease, and the Risk of Kidney Stones
    Zhang, Fan
    Li, Wenjian
    KIDNEY & BLOOD PRESSURE RESEARCH, 2025, 50 (01) : 115 - 130
  • [38] A gut microbiome signature for HIV and metabolic dysfunction-associated steatotic liver disease
    Martinez-Sanz, Javier
    Talavera-Rodriguez, Alba
    Diaz-Alvarez, Jorge
    Rosas Cancio-Suarez, Marta
    Rodriguez, Juan Miguel
    Alba, Claudio
    Montes, Maria Luisa
    Martin-Mateos, Rosa
    Burgos-Santamaria, Diego
    Moreno, Santiago
    Serrano-Villar, Sergio
    Sanchez-Conde, Matilde
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [39] Non-invasive testing in metabolic dysfunction-associated steatotic liver disease
    Dawod, Sanad
    Brown, Kimberly
    FRONTIERS IN MEDICINE, 2024, 11
  • [40] Metabolic Dysfunction-Associated Steatotic Liver Disease: Pathogenetic Links to Cardiovascular Risk
    Ionescu, Vlad Alexandru
    Gheorghe, Gina
    Bacalbasa, Nicolae
    Diaconu, Camelia Cristina
    BIOMOLECULES, 2025, 15 (02)